GIST (Gastrointestinal Stromal Tumor) Clinical Trials

About GIST (Gastrointestinal Stromal Tumor) trials

Mutation status drives GIST therapy more than almost any other oncology setting, with each genotype guiding both standard treatment and trial selection. KIT mutations occur in 75-80% of GIST and are the foundational driver, with exon 11 mutations being the most common and most imatinib-sensitive, exon 9 mutations requiring higher imatinib dosing, and exon 13 / 17 mutations conferring resistance to first-line therapy. PDGFRA mutations occur in roughly 10% of GIST; the PDGFRA D842V mutation is imatinib-resistant and is the indication for avapritinib as first-line therapy, while other PDGFRA mutations are imatinib-sensitive. NF1 alterations identify GIST associated with neurofibromatosis type 1, which behaves differently and gates separate trial considerations. SDHA and SDHB deficiency identify a distinct GIST subset (often called SDH-deficient or "wild-type" GIST), more common in pediatric and young adult patients and in Carney triad, that responds poorly to standard TKIs and gates dedicated trials testing novel approaches.

Active trials in GIST split by mutation status and prior TKI exposure. Front-line GIST trials test imatinib alternatives or combinations for newly diagnosed metastatic disease, with mutation-specific dosing strategies. PDGFRA D842V trials test avapritinib combinations and next-generation agents because this mutation is imatinib-resistant from the start. Post-imatinib trials test sunitinib alternatives and combinations for second-line. Heavily pretreated trials (post-imatinib, post-sunitinib, post-regorafenib, post-ripretinib) test novel mechanisms because patients have exhausted approved TKI lines. SDH-deficient GIST trials are a distinct space testing novel approaches because these tumors don't respond well to standard TKIs; trials in this group often include pediatric and young adult cohorts. Adjuvant trials test imatinib duration and intensification for resected high-risk GIST. Combination trials test TKI + IO or TKI + targeted combinations to extend response duration or overcome resistance.

GIST trial screening typically checks mutation status and prior TKI line. Mutation status testing is foundational because most GIST trials are mutation-restricted: KIT exon 11 vs exon 9 vs exon 13/17, PDGFRA D842V vs other PDGFRA, SDHA / SDHB-deficient, NF1-associated. Prior imatinib exposure (and which dose) is the standard front-line for metastatic GIST, with most R/R trials specifying imatinib-pretreated. Prior sunitinib, regorafenib, ripretinib, and avapritinib exposure matter for line-specific trials, with TKI line counts determining which trials apply. Adjuvant vs metastatic disease state. SDH-deficient trials are typically open to younger patients and may include pediatric cohorts. Performance status, with most trials accepting ECOG 0-2. Adequate organ function, with cardiac considerations for some TKIs.

Biomarkers tested in GIST (Gastrointestinal Stromal Tumor) trials

These are the molecular markers most commonly required or evaluated in GIST (Gastrointestinal Stromal Tumor) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.